Compare Amgen, Inc. (AMGN) vs IAC/Interactivecorp (PPLI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs IAC/Interactivecorp — how do they compare? Amgen, Inc. trades at $356.37 (market cap $196.12B), while IAC/Interactivecorp trades at $46.51 (market cap $3.46B). The key difference: Amgen, Inc. is far larger — about 56.7× IAC/Interactivecorp's market cap, and Amgen, Inc. pays a 2.77% dividend while IAC/Interactivecorp pays none. Which is the better fit depends on your goals.
| AMGN | PPLI | |
|---|---|---|
Market Cap | $196.12B | $3.46B |
Sector | Health | Media |
52-Week High | $388.16 | $47.62 |
52-Week Low | $271.18 | $31.52 |
Enterprise Value | $241.41B | $3.77B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
PPLI trades at $46.50, down 2.13% on the day, near its 52-week high. The stock shows bullish technical signals with strong moving average support, though RSI levels suggest overbought conditions. Fundamentally, revenue has declined from $5.2B in 2022 to $2.4B in 2025, with recent quarters missing EPS expectations. The company maintains a high gross margin of 66.49% but struggles with profitability, posting a net loss of $104M in 2025. Analyst consensus remains bullish with a $55.40 price target, while recent news questions valuation after a 3.6% rally.
PPLI presents a mixed outlook with bullish analyst sentiment against challenging fundamentals. The 63.64% buy rating and 25% upside to consensus target reflect optimism for a turnaround, but consecutive earnings misses and negative cash flow pose significant execution risks. Investors face volatility from inconsistent profitability despite attractive valuation metrics like P/B of 0.76. The key catalyst remains demonstrating sustainable earnings growth amid declining revenues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About IAC/Interactivecorp
IAC Inc is an Internet media company with segments that include Angi (47% of total revenue), Dotdash (10%), search (24%), and emerging and other (19%). The firm spun off the narrow-moat dating app provider Match Group in second-quarter 2020 and the no-moat video software provider Vimeo in second-quarter 2021.
Read more on PPLI →
